IBD Biosimilar Inflectra Approved by TGA

IBD Biosimilar Inflectra Approved by TGA
Patient advocacy groups and the biotech industry are heralding the development and approval of biosimilars as a new day for the Inflammatory Bowel Disease's (IBD) treatment. After the launching of the first Biosimilar Monoclonal Antibody in Europe in February and the presentation of promising research updates on the biosimilar Inflectra at the 2015 ECCO-IBD Conference,  Hospira is now announcing that Inflectra (infliximab) has been registered as a therapy in Australia. A total of eight inflammatory conditions can be treated with Inflectra, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (AS), adult and pediatric Crohn's disease, refractory fistulising Crohn's disease, adult and pediatric ulcerative colitis, and plaque psoriasis. Inflectra is an artificial compound that is biologicaly similar to Remicade® (infliximab). As a biosimilar, Inflectra has been developed to mimic the high standards of biologic manufacturing to treat the same disease as the original product. Moreover, it is anticipated that Inflectra will reduce the cost of the original therapy up to 30%. Inflectra was designed to have the same efficacy, safety and quality as Remicade, the original (and considerably more expensive) monoclonal antibody (mAb). Last year, more than $100 million was invested by the
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *